John B Patterson
Overview
Explore the profile of John B Patterson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
1379
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Unal B, Kuzu O, Jin Y, Osorio D, Kildal W, Pradhan M, et al.
Nat Commun
. 2024 Oct;
15(1):8895.
PMID: 39406723
Unfolded protein response (UPR) is a central stress response pathway that is hijacked by tumor cells for their survival. Here, we find that IRE1α signaling, one of the canonical UPR...
2.
Sheng X, Nenseth H, Qu S, Kuzu O, Frahnow T, Simon L, et al.
Nat Commun
. 2024 Jul;
15(1):6190.
PMID: 39043728
No abstract available.
3.
Dastghaib S, Shojaei S, Mostafavi-Pour Z, Sharma P, Patterson J, Samali A, et al.
Cells
. 2024 Apr;
13(8).
PMID: 38667338
In the original publication [...].
4.
Salimi A, Schemionek-Reinders M, Huber M, Vieri M, Patterson J, Alten J, et al.
J Cell Mol Med
. 2023 Sep;
27(21):3363-3377.
PMID: 37753803
Activating point mutations of the RAS gene act as driver mutations for a subset of precursor-B cell acute lymphoblastic leukaemias (pre-B ALL) and represent an ambitious target for therapeutic approaches....
5.
Lhomond S, Avril T, Dejeans N, Voutetakis K, Doultsinos D, McMahon M, et al.
EMBO Mol Med
. 2023 Feb;
15(2):e16731.
PMID: 36752056
No abstract available.
6.
Creedican S, Robinson C, Mnich K, Islam M, Szegezdi E, Clifford R, et al.
J Cell Mol Med
. 2022 Jul;
26(16):4629-4633.
PMID: 35822520
No abstract available.
7.
Lhomond S, Avril T, Dejeans N, Voutetakis K, Doultsinos D, McMahon M, et al.
EMBO Mol Med
. 2022 Jan;
14(2):e15622.
PMID: 35014200
No abstract available.
8.
Dastghaib S, Shojaei S, Mostafavi-Pour Z, Sharma P, Patterson J, Samali A, et al.
Cells
. 2020 Oct;
9(11).
PMID: 33105603
Glioblastoma (GBM) is the most prevalent malignant primary brain tumor with a very poor survival rate. Temozolomide (TMZ) is the common chemotherapeutic agent used for GBM treatment. We recently demonstrated...
9.
Vieri M, Preisinger C, Schemionek M, Salimi A, Patterson J, Samali A, et al.
Carcinogenesis
. 2020 Sep;
42(2):272-284.
PMID: 32915195
BCR-ABL1-positive acute lymphoblastic leukemia (ALL) cell survival is dependent on the inositol-requiring enzyme 1 alpha (IRE1α) branch of the unfolded protein response. In the current study, we have focused on...
10.
Le Reste P, Pineau R, Voutetakis K, Samal J, Jegou G, Lhomond S, et al.
Cancer Lett
. 2020 Sep;
494:73-83.
PMID: 32882336
Glioblastoma multiforme (GBM) is the most severe primary brain cancer. Despite an aggressive treatment comprising surgical resection and radio/chemotherapy, patient's survival post diagnosis remains short. A limitation for success in...